Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test

Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min... Background Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and often lasting side effect of cancer treat- ment, with increasing CIPN severity associated with increasing deficits in balance, gait, and mobility. The 6-min walk test (6MWT) is a widely validated and utilized measure of general physical functioning and mobility, although its utility in a CIPN context is unclear. This study aimed to determine the utility of the 6MWT as an assessment of mobility deficits in a CIPN cohort and utilize the 6MWT to compare mobility data from CIPN patients to those of healthy and clinical populations. Methods Cancer survivors exposed to neurotoxic chemotherapies (N = 100; mean 17 ± 13 months post-treatment; mean age 59 ± 13 years) completed a single cross-sectional assessment of patient-reported and objective CIPN, mobility (6MWT), and disability. Results CIPN symptoms were reported in the majority of the cohort (87%). Increasing age, patient-reported and objective CIPN symptoms, and disability were associated with decreasing 6MWT distance (.48 ≤ R ≤ .63; p < .001) in bivariate models. Multiple regression models of 6MWT distance included age, sex, and patient-reported or objective CIPN severity as significant indepen- dent correlates (.62 ≤ R ≤ .64; p < .03). 6MWT distances http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cancer Survivorship: Research and Practice Springer Journals

Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/mobility-in-survivors-with-chemotherapy-induced-peripheral-neuropathy-5mriuWsikp

References (53)

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Public Health; Oncology; Health Promotion and Disease Prevention; Health Informatics; Quality of Life Research; Primary Care Medicine
ISSN
1932-2259
eISSN
1932-2267
DOI
10.1007/s11764-019-00769-7
Publisher site
See Article on Publisher Site

Abstract

Background Chemotherapy-induced peripheral neuropathy (CIPN) is a significant and often lasting side effect of cancer treat- ment, with increasing CIPN severity associated with increasing deficits in balance, gait, and mobility. The 6-min walk test (6MWT) is a widely validated and utilized measure of general physical functioning and mobility, although its utility in a CIPN context is unclear. This study aimed to determine the utility of the 6MWT as an assessment of mobility deficits in a CIPN cohort and utilize the 6MWT to compare mobility data from CIPN patients to those of healthy and clinical populations. Methods Cancer survivors exposed to neurotoxic chemotherapies (N = 100; mean 17 ± 13 months post-treatment; mean age 59 ± 13 years) completed a single cross-sectional assessment of patient-reported and objective CIPN, mobility (6MWT), and disability. Results CIPN symptoms were reported in the majority of the cohort (87%). Increasing age, patient-reported and objective CIPN symptoms, and disability were associated with decreasing 6MWT distance (.48 ≤ R ≤ .63; p < .001) in bivariate models. Multiple regression models of 6MWT distance included age, sex, and patient-reported or objective CIPN severity as significant indepen- dent correlates (.62 ≤ R ≤ .64; p < .03). 6MWT distances

Journal

Journal of Cancer Survivorship: Research and Practice – Springer Journals

Published: Jun 6, 2019

There are no references for this article.